Latest Operating Costs News

EcoGraf Limited advances key milestones in its vertically integrated battery anode materials business, including nearing completion of debt financing for the Epanko Graphite Project and securing a pivotal HFfree purification patent.

Vanadium Resources Limited is advancing its Steelpoortdrift project with fresh leadership, a successful equity raise, and a strategic pivot towards higher-margin concentrate production alongside direct shipping ore.

Hartshead Resources has secured a Well Carry Agreement with RockRose Energy, reducing its equity stake while RockRose funds critical Phase C well costs. The company also seeks a two-year licence extension amid regulatory delays, maintaining a strong cash position and clear development plans.

LCL Resources reports promising trenching results at its Ubei project in Papua New Guinea, including a standout grab sample with nearly 8g/t gold, while advancing exploration and strategic options in Colombia.

RocketBoots Limited has secured new trial contracts worth $208,000 with major retail banks in Australia and Mexico, while expanding its international sales pipeline and appointing a seasoned CFO/COO to support growth.

Riversgold has secured a full funding and operational partnership with MEGA Resources for its Northern Zone Gold Project near Kalgoorlie, while also farming out its Saint John project in Canada to AIS Resources. The company raised A$1.8 million to advance exploration and development.

Jameson Resources has made significant strides in advancing its Crown Mountain Hard Coking Coal Project, progressing environmental assessments and Indigenous partnerships while securing fresh capital to support development.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.

Stakk Limited reports a staggering 1,836% year-on-year increase in quarterly receipts, positioning itself on track to hit an $8 million annual recurring revenue target by mid-2026.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.